Bill Commons

NY S 10136

in committee

Relates to capping cost sharing for antiviral COVID-19 therapeutics

New York · 2025-2026 Regular Session · upper

Quick answers

Did NY S 10136 pass?

Not yet. NY S 10136 is in committee as of 2026-04-30 and has not come to a final vote. Latest recorded action (2026-04-30): REFERRED TO INSURANCE

What is NY S 10136 about?

Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.

Who sponsors NY S 10136?

Erik Bottcher is the primary sponsor of NY S 10136.

Description

Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.

Introduced
Latest action
2026-04-30 — REFERRED TO INSURANCE
Bill type
bill
Last updated

Sponsors

  • Erik Bottcherprimary

Committees

Not provided by source.

Action timeline

  1. 2026-04-30

    REFERRED TO INSURANCE

    referral-committee

Versions

Documents

Votes

Not provided by source.

Related bills

  • Prior session: S 8367not in this corpus
  • Prior session: S 6925not in this corpus

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z

Inspect retained evidence for changes recorded after evidence tracking began:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=S 10136. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.